Richard J. A. Goodwin

Statistics

Publications

Citations

4.3K

H-Index

Active since

2008

Affiliations

AstraZeneca (United Kingdom)(Current)

University of Glasgow

Uppsala University

National Physical Laboratory

Imperial College London

Richard J. A. Goodwin is an author at AstraZeneca (United Kingdom) specializing in mass spectrometric analysis, mass spectrometric imaging, and pharmacology.

ORCID

Publications per year

2008–2025

Publications

The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer

Arafath K. Najumudeen, Fatih Ceteci, Sigrid K. Fey et al. · Nature Genetics · 2021 · 329 citations · Full text

Medicine, Molecular Biology, Oncology +12

Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs

Nicola Colclough, Kan Chen, Peter Johnström et al. · Clinical Cancer Research · 2020 · 233 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

Susan Ashton, Young Ho Song, Elaine Cadogan et al. · Science Translational Medicine · 2016 · 220 citations

Pharmacy, Oncology, Pharmacology +17

Direct Targeted Quantitative Molecular Imaging of Neurotransmitters in Brain Tissue Sections

Mohammadreza Shariatgorji, Anna Nilsson, Richard J. A. Goodwin et al. · Neuron · 2014 · 216 citations · Full text

Life Sciences, Neurobiology, Neuroscience +14

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Stefanie Mullins, John P. Vasilakos, Katharina Deschler et al. · Journal for ImmunoTherapy of Cancer · 2019 · 204 citations · Full text

Life Sciences, Immunology, Oncology +17

1–5 of 77